Skip to main content
Kisqali patient portrayal.

MONALEESA-7 safety profile

KISQALI + AI in 1L premenopausal patients

Scheduled blood tests and 2 upfront ECGs help to ensure your patients start KISQALI with confidence


Review the assessments schedule and the incidence of QT prolongation across clinical trials

The majority of adverse reactions with KISQALI were manageable and reversible


Review dose adjustment guidance

Resource thumbnail

KISQALI Treatment Guide

A comprehensive guide to treatment with KISQALI + AI that includes dedicated sections to support you in treating your patients with early (stage II or III at high risk of recurrence) or metastatic HR+/HER2- breast cancer.
Download
Resource thumbnail

KISQALI LFT Brochure

A clinical brochure that discusses the data on potential liver-related events with KISQALI in HR+/HER2- eBC and mBC, including monitoring and management.
Download
eBC, early breast cancer; GGT, gamma-glutamyl transferase; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mBC, metastatic breast cancer.

References: 1. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915. doi:10.1016/S1470-2045(18)30292-4 2. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472. doi:10.1200/JCO.2018.78.9909 3. Data on file. CLEE011A2301. Novartis Pharmaceuticals Corp; 2016. 4. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp. 5. Yardley DA, Yap YS, Azim HA, et al. Pooled exploratory analysis of survival in patients with HR+/HER2− advanced breast cancer and visceral metastases treated with ribociclib + endocrine therapy in the MONALEESA trials. Poster presented at: ESMO Congress 2022; September 9-13, 2022; Paris, France. Poster 205P.